The Asia-pacific market for Nuclear Medicine/Radiopharmaceuticals is estimated at USD 1.25 billion in 2020 and is expected to reach $2.43 billion by 2025, growing at a CAGR of 14.3%.
Increasing incidences of cancer diseases and cardiovascular problems is a crucial driving factor for the market to grow. Rising geriatric population is one of the factors propelling the demand of the Nuclear Medicine/Radiopharmaceuticals market in the Asia Pacific. Increasing focus on the development of new drugs in radiopharmaceuticals is surging the need of the market. Besides, improvement in treatment options such as chemotherapy and surgery for cancer diseases is lavishing this market's growth rate in the Asia Pacific. The main advantage of nuclear medicine is its effective treatment procedure. It performs targeted therapies where it only affects cancerous cells and does not disturb healthy cells in the specific area. The attribute, as mentioned above, is escalating the growth of the market to the extent.
However, nuclear medicines have a short life span, a major hindering factor for market growth. Fluctuations in the availability of different raw materials and the shortage of skilled persons in performing the latest diagnostic procedures are slightly restraining the APAC Nuclear Medicine/Radiopharmaceuticals market. Rapid changes in economic strategies may also show a negative impact on the demand of the market.
The emergence of the latest technological developments in the medical sector and the launch of innovative products in favor of the end-users is solely to promote growth opportunities for the market. Growing disposable income, especially in urban areas, is also a common factor fueling the Nuclear Medicine/Radiopharmaceuticals market's growth. Increasing concern towards the patient’s health condition and evaluating the patient's well-being after treatment is accelerating the demand for this market. The trend towards targeted treatment procedures, which is having a high success rate, is leveraging the market's growth.
This research report on the Asia Pacific Nuclear Medicine/Radiopharmaceuticals Market has been segmented and sub-segmented into the following categories:
Regionally, Asia Pacific is leading with dominant shares of the market from the past few years and has hit the highest CAGR in the coming years. India and China are among the major countries contributing the most top shares for the market growth. Increasing investments in hospitals and diagnostic centers by private and public sectors greatly influence the demand of the market. Growing revenue in these countries is also ascribed to spur the growth rate of the market. Japan is following India and China in accounting for the most significant shares of the market with the increasing product launches with advanced technology in the medical sector. Also, rising applications of nuclear medicine in neurology is prompting the growth rate of this market.
Major companies dominating the APAC Nuclear Medicine/Radiopharmaceuticals Market analyzed in this report are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Diagnostic Radioisotopes
5.1.1.1 SPECT
5.1.1.1.1 Technetium-99m
5.1.1.1.2 Thallium-201
5.1.1.1.3 Gallium-67
5.1.1.1.4 Iodine-23
5.1.1.1.5 Others
5.1.1.2 PET
5.1.1.2.1 Fluorine-18
5.1.1.2.2 Rubidium-82
5.1.1.2.3 Others
5.1.2 Therapeutic Radioisotopes
5.1.2.1 Beta Emitters
5.1.2.1.1 Iodine-131
5.1.2.1.2 Yttrium-90
5.1.2.1.3 Samarium-153
5.1.2.1.4 Rhenium-186
5.1.2.1.5 Lutetium-177
5.1.2.2 Alpha Emitters
5.1.2.2.1 Radium-223
5.1.2.3 Brachytherapy
5.1.2.3.1 Cesium-131
5.1.2.3.2 Iodine-125
5.1.2.3.3 Palladium-103
5.1.2.3.4 Iridium-192
5.2 By Application
5.2.1 Cardiology
5.2.2 Lymphoma
5.2.3 Thyroid
5.2.4 Neurology
5.2.5 Oncology
5.2.6 Others
6. Geographical Analysis
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 GE Healthcare
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Hologic Inc.
8.3 Segami Corporation
8.4 Positron Corporation
8.5 Bracco Imaging S.P.A
8.6 Naviscan Inc.
8.7 Bayer Healthcare
8.8 Lantheus Medical Imaging Inc.
8.9 IBA Molecular Imaging
8.10 Medix Inc.
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
